RESOMER RG 755 S Bioresorbable PLGA Drug Delivery Grade is an ester-terminated poly(D,L-lactide-co-glycolide) copolymer with a 75:25 molar ratio of D,L-lactide to glycolide. The grade is identified by CAS registry number 26780-50-7 and belongs to the RESOMER family of bioresorbable synthetic aliphatic polyesters supplied for pharmaceutical and medical-device formulation. The copolymer backbone consists of ester-linked lactoyl and glycoloyl repeat units, and the terminal ester architecture distinguishes the grade from acid-capped analogues. This structural characteristic influences water uptake, hydrolytic chain scission, and the autocatalytic contribution of chain-end carboxylic acid groups during degradation.

The principal specification for lot release is inherent viscosity, specified at 0.50–0.70 dL/g when measured as a 0.1% solution in chloroform at 25 °C. Inherent viscosity functions as a polymer-chain-length index rather than a direct molecular-mass release criterion. The grade is amorphous under normal thermal history; therefore glass transition, rather than melting temperature, controls dimensional stability and processing. The drug delivery designation indicates that the polymer is intended for controlled-release matrices, including parenteral microspheres, nanoparticles, subcutaneous implants, in situ forming depots, and solid dispersions. The polymer itself is an excipient, not a finished dosage form, and its use in a specific drug product requires final-product qualification according to applicable pharmacopeial and regulatory standards.

Which specification parameters control lot-to-lot reproducibility for RG 755 S?

Batch-to-batch consistency is governed by the combined control of copolymer composition, chain architecture, residual monomer content, residual solvent content, moisture content, and glass transition behavior. The D,L-lactide-to-glycolide ratio is maintained at 75:25 on a molar basis, and deviation from this ratio shifts hydrolytic degradation kinetics because glycolide-rich copolymers exhibit greater hydrophilicity and faster ester hydrolysis. The ester terminus is specified by the manufacturer designation; the absence of a dominant terminal carboxylic acid population lowers the initial acid number and reduces the early-stage autocatalytic hydrolysis that is characteristic of the H-series grades.

Residual monomer and solvent controls are critical because both species plasticize the polymer and can alter initial release, microsphere porosity, and glass transition. Representative manufacturer release limits for residual monomers and residual solvents are typically ≤ 0.5% each, with water content controlled to ≤ 0.5% by Karl Fischer titration. The polymer is soluble in dichloromethane, chloroform, tetrahydrofuran, acetone, and ethyl acetate, and is insoluble in water. Because solubility in halogenated solvents enables emulsion-based microencapsulation, residual dichloromethane or chloroform must be reduced below the limits of ICH Q3C before administration of the final product.

Molecular weight measured by gel permeation chromatography is frequently reported in research literature, but it is not the release specification for this grade. Comparisons of molecular weight across laboratories should state the calibration standard, commonly polystyrene, because absolute molecular weight values differ when determined by light scattering or viscometry. The inherent viscosity specification remains the more reproducible release index for incoming raw-material acceptance testing and for monitoring hydrolytic degradation after processing. Certificate-of-analysis review should include the batch-specific values for residual tin catalyst, sulfated ash, and any additional manufacturer-reported limits that apply to parenteral or implant applications.

Storage and handling directly influence specification stability. The polymer should be stored at 2–8 °C in a sealed container under dry inert gas or desiccant. Prolonged exposure to relative humidity above 60% can increase absorbed moisture, and the polymer should be re-dried by vacuum at ambient temperature until water content returns to ≤ 0.5% before melt processing. Because polyester hydrolysis is accelerated by moisture, elevated temperature, and acidic or basic contaminants, the material should not be combined with strong oxidizers, strong acids, or nucleophilic amines that can cleave the polyester backbone during compounding or terminal sterilization.

Emulsion, spray-drying, and hot-melt processing pathways

Solvent-based microencapsulation is the most widely reported processing route for this viscosity grade. In emulsion-solvent evaporation, the copolymer is dissolved in a water-immiscible solvent such as dichloromethane or chloroform, and the drug is either dissolved or dispersed in the organic phase. A primary water-in-oil emulsion or solid-in-oil dispersion is then formed under high-shear rotor-stator homogenization, followed by solvent extraction or evaporation into an aqueous continuous phase. The resulting microspheres are washed, collected by filtration or centrifugation, and dried. The viscosity of the 0.50–0.70 dL/g grade is high enough to form coherent microspheres with controlled initial release but low enough to permit practical solvent concentrations in the organic phase without excessive solution viscosity.

Spray-drying is an alternative solvent-removal method that converts a polymer-drug solution or suspension into dried microparticles in a single continuous step. The process uses a spray-drying apparatus with controlled inlet temperature, atomization gas flow, and solvent-condensation recovery. Because the polymer is amorphous, the drying temperature must be balanced against the glass transition; excessive outlet temperature can produce particle agglomeration, while insufficient drying leaves residual solvent above the ICH Q3C limit. Vacuum post-drying is commonly required after spray-drying to reduce residual dichloromethane or ethyl acetate to acceptable levels.

Hot-melt extrusion is applicable when the drug substance is thermally stable and when a dense implant or solid dispersion is required. Continuous twin-screw extruders with length-to-diameter ratios of 25:1 to 40:1 are used for polyester-based implants, but published data for this specific grade under continuous extrusion is limited. Barrel set points should be maintained below the point at which the polymer undergoes rapid thermal hydrolysis; typical processing temperatures for 75:25 PLGA are below 130 °C, although the actual window depends on residence time, screw design, and residual moisture. Post-extrusion inherent viscosity must be measured to confirm that chain scission has not moved the polymer outside the intended degradation profile. Terminal sterilization by gamma irradiation at 25 kGy may reduce molecular weight through chain scission; therefore post-sterilization viscosity and drug-release verification are required for implantable products.

For in situ forming depots, the polymer is dissolved in a pharmaceutically acceptable organic solvent such as N-methyl-2-pyrrolidone or dimethyl sulfoxide. Upon injection into an aqueous physiological environment, the solvent exchanges with water and the polymer precipitates to form a depot. The solvent choice, polymer concentration, and drug loading determine the initial release phase and the depot morphology. Residual solvent evaluation is especially important for this route because the solvent remains in the injected solution at the time of administration and must meet the intended regulatory limits for the final product.

In comparative formulation work, RESOMER RG 755 S occupies an intermediate position within the 75:25 PLGA viscosity series. Against RESOMER RG 752 S, which has a lower inherent viscosity range of 0.16–0.24 dL/g, the RG 755 S grade produces higher solution viscosity and typically yields microspheres with slower initial release and longer hydrolytic erosion. However, the higher viscosity also requires lower polymer concentrations or higher solvent-to-polymer ratios to maintain processable emulsion viscosity. Against RESOMER RG 756 S, with a reported inherent viscosity range of 0.70–1.0 dL/g, RG 755 S dissolves more readily in common process solvents and degrades somewhat faster because of the lower average chain length.

The difference from 50:50 PLGA grades is more pronounced. A 50:50 copolymer contains a higher glycolide fraction and therefore undergoes faster water uptake and hydrolytic cleavage than a 75:25 copolymer. RG 755 S is more hydrophobic and is generally selected when release durations beyond approximately 4–8 weeks are required from a PLGA matrix, although the actual release profile is formulation-specific and cannot be assigned solely by copolymer ratio. The ester-terminated architecture also differentiates RG 755 S from the corresponding acid-terminated 75:25 H-series grade. The H-series polymer carries a free carboxylic acid chain end that increases the initial acid number, accelerates water penetration, and promotes faster initial degradation through chain-end autocatalysis.

The selection of RG 755 S over an acid-terminated analogue is therefore partly a function of the desired degradation lag phase. Ester-capped PLGA typically exhibits slower early-stage mass loss and may reduce the burst release of weakly basic or poorly water-soluble drugs that interact with free carboxylic acid groups. However, for peptide or protein formulations, an acid-terminated grade may be preferred if electrostatic interaction with the peptide is beneficial for encapsulation efficiency; the choice must be experimentally verified because the interaction depends on the isoelectric point, peptide sequence, and organic-phase solvent system.

When terminal carboxylic acid content is introduced by selecting an H-series analogue

Replacing the ester terminus of RG 755 S with a free carboxylic acid terminus increases the hygroscopicity of the copolymer and shifts the degradation mechanism toward a more autocatalytic profile. The acid terminus contributes a proton source that accelerates ester hydrolysis in the immediate polymer environment, and the resulting hydrophilic chain end can facilitate water uptake. In microsphere formulations, this change can shorten the release lag phase and reduce the molecular mass retention time. However, the same effect can destabilize acid-labile drug substances during storage or release, and the higher acid number may increase the extent of peptide acylation or esterification at the polymer chain end during long-term incubation.

For applications requiring terminal sterilization, the ester-terminated RG 755 S grade may tolerate slightly lower chain scission than an acid-terminated analogue under equivalent irradiation dose because the initial free carboxylic acid content is lower. Nevertheless, published data for this specific configuration is limited, and the effect of terminal chemistry on radiation-induced degradation should be confirmed experimentally for each formulation. Biocompatibility of the final medical device or drug product must be established according to ISO 10993-1 and relevant subsequent parts of the series; the polymer certificate of analysis alone does not provide finished-product biological safety. Residual solvents must be controlled to ICH Q3C limits, and endotoxin control must be addressed during downstream isolation of the microspheres or implants. The polymer is not inherently sterile, and storage under clean conditions does not replace terminal sterilization or aseptic processing.

RESOMER RG 755 S is therefore a mid-viscosity, ester-capped 75:25 PLGA grade for drug delivery systems that require a balance between organic-phase processability and extended hydrolytic degradation. Its differentiation from lower-viscosity, higher-viscosity, 50:50 PLGA, and acid-terminated analogues is defined by the combined effects of copolymer ratio, chain length, and terminal chemistry. These properties must be evaluated in the context of the specific drug substance, loading, microarchitecture, and regulatory route rather than as isolated polymer attributes.